2021
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis
Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.Peer-Reviewed Original ResearchConceptsStage IV melanomaMetastatic brain lesionsStage IIIInitial diagnosisTumor RegistryOverall incidenceBrain lesionsBM incidenceSingle-institute retrospective analysisBM developmentBrain metastases incidenceIncidence of BMInstitution's tumor registryStage III patientsTime of diagnosisMetastatic intracranial lesionsCommon genetic mutationsTumor genetic profileGenetic profileBM occurrenceMedian durationAdvanced melanomaSurveillance regimenIII patientsMedian time
2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy